Jefferies Group cut shares of uniQure NV (NASDAQ:QURE) from a buy rating to a hold rating in a report published on Monday. The brokerage currently has $8.00 price target on the stock, down from their previous price target of $28.00.

A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of uniQure NV from a sell rating to a hold rating in a research note on Wednesday, September 21st. Piper Jaffray Cos. set a $16.00 price objective on shares of uniQure NV and gave the company a buy rating in a research note on Friday, August 19th. Chardan Capital reissued a buy rating and issued a $12.00 price objective (down from $20.00) on shares of uniQure NV in a research note on Tuesday, November 15th. Leerink Swann reissued an outperform rating and issued a $27.00 price objective on shares of uniQure NV in a research note on Monday, August 29th. Finally, HC Wainwright initiated coverage on shares of uniQure NV in a research note on Thursday, August 4th. They issued a buy rating and a $21.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $22.70.

Analyst Recommendations for uniQure NV (NASDAQ:QURE)

uniQure NV (NASDAQ:QURE) opened at 6.64 on Monday. uniQure NV has a 1-year low of $6.41 and a 1-year high of $20.22. The stock has a 50 day moving average price of $7.14 and a 200-day moving average price of $8.45. The firm’s market cap is $166.86 million.

ILLEGAL ACTIVITY WARNING: “uniQure NV (QURE) Downgraded to Hold at Jefferies Group” was published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of United States & international copyright legislation. The correct version of this story can be viewed at http://www.dailypolitical.com/2016/11/29/uniqure-nv-qure-downgraded-to-hold-at-jefferies-group.html.

Hedge funds have recently modified their holdings of the company. Baker BROS. Advisors LP acquired a new stake in shares of uniQure NV during the third quarter valued at $1,760,000. BlackRock Institutional Trust Company N.A. boosted its stake in shares of uniQure NV by 200.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 70,322 shares of the company’s stock valued at $538,000 after buying an additional 46,905 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of uniQure NV by 121.1% in the third quarter. JPMorgan Chase & Co. now owns 31,340 shares of the company’s stock valued at $240,000 after buying an additional 17,166 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in shares of uniQure NV during the third quarter valued at $111,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of uniQure NV by 105.7% in the second quarter. Point72 Asset Management L.P. now owns 562,447 shares of the company’s stock valued at $4,145,000 after buying an additional 288,982 shares in the last quarter. 28.16% of the stock is currently owned by institutional investors.

uniQure NV Company Profile

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.